Mononuclear phagocytes and rheumatoid synovitis: Mastermind or workhorse in arthritis?

Arthritis and Rheumatism

Volumn 40, Issue 1, 1997, Pages 5-18

  Burmester, Gerd R ^a   Stuhlmüller, Bruno ^a   Keyszer, Gernot ^a   Kinne, Raimund W ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY INFILTRATE; LEUKOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; T LYMPHOCYTE ACTIVATION;

EID: 0342578133     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400104     Document Type: Review

References (178)

1. Allison AC, Ferluga J, Prydz H, Schorlemmer HU: The role of macrophage activation in chronic inflammation. Agents Actions 8:27-35, 1978
2. Palmer DG: The anatomy of the rheumatoid lesion. Br Med Bull 51:286-295, 1995
3. Klareskog L, Forsum U, Kabelitz D, Plöen L, Sundström C, Nilsson K, Wigren A, Wigzell H: Immune functions of human synovial cells: phenotypic and T cell regulatory properties of macrophage-like cells that express HLA-DR. Arthritis Rheum 25:488-501, 1982
4. Seitz M, Hunstein W: Enhanced prostanoid release from monocytes of patients with rheumatoid arthritis and active lupus erythematosus. Ann Rheum Dis 44:438-445, 1985
5. Hahn G, Stuhlmüller B, Hain N, Kalden JR, Pfizenmaier K, Burmester GR: Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy. J Clin Invest 91:862-870, 1993
6. Firestein GS, Alvaro-Gracia JM, Maki R: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144:3347-3353, 1990
7. Steven MM, Lennie SE, Sturrok RD, Gemmell CG: Enhanced bacterial phagocytosis by peripheral blood monocytes in rheumatoid arthritis. Ann Rheum Dis 43:435-439, 1984
8. Horneff G, Sack U, Kalden JR, Emmrich F, Burmester GR: Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment: decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol 91:207-213, 1993
9. Yanni G, Nabil M, Farahat MR, Poston RN, Panayi GS: Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid arthritis synovial membrane. Ann Rheum Dis 53:315-322, 1994
10. Papadimitriou JM, Ashman RB: Macrophages: current views on their differentiation, structure, and function. Ultrastruct Pathol 13:343-372, 1989
11. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dentritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1108-1118, 1994
12. Caux C, Dezutter-Dambuyant C, Schmitt D, Bancherau J: GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360:258-261, 1992
13. Reid CD, Stackpoole A, Maeger A, Tikerpae J: Interaction of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dentritic cell growth from early bipotent CD34 + progenitors in human bone marrow. J Immunol 149:2681-2688, 1992
14. Steinman RM, Swanson J: The endocytic activity of dendritic cells. J Exp Med 182:283-288, 1995
15. Thomas R, Lipsky PE: Presentation of self peptides by dendritic cells: possible implications for the pathogenesis of rheumatoid arthritis. Arthritis Rheum 39:183-190, 1996
16. Watrous DA, Andrews BS: The metabolism and immunology of bone. Semin Arthritis Rheum 19:45-65, 1989
17. Rittig MG, Häupl T, Burmester GR: Coiling phagocytosis: a way for MHC class I presentation of bacterial antigens? Int Arch Allergy Immunol 103:4-10, 1994
18. Rittig M, Krause A, Häupl T, Schaible UE, Modolell M, Kramer MD, Lütjen-Drecoll E, Simon MM, Burmester GR: Coiling phagocytosis is the preferential phagocyte mechanism for Borrelia burgdorferi. Infect Immun 60:4205-4212, 1992
19. Rittig M, Häupl T, Krause A, Kressel M, Groscurth P, Burmester GR: Borrelia burgdorferi-induced ultrastructural alterations in human phagocytes: a clue to pathogenicity? J Pathol 173:269-282, 1994
20. Rittig M, Kressel M, Häupl T, Burmester GR: Sectional uptake and cytosolic processing of Borrelia burgdorferi by human phagocytes. In, Lyme Borreliosis. Edited by JS Axford, DHE Rees. New York, Plenum Press, 1994
21. Hasanuma T, Nakajima T, Aono H, Sato K, Matsubara T, Yamamoto K, Nishioka K: Establishment and characterization of synovial cell clones with integrated human T-cell leukemia virus type-1. Clin Immunol Immunopathol 72:90-97, 1994
22. Nepom GT, Erlich H: MHC class-II molecules and autoimmunity. Annu Rev Immunol 9:493-525, 1991
23. Ranheim EA, Kipps TJ: Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis. Arthritis Rheum 37:1637-1646, 1994
24. Liu MF, Kohsaka H, Sakurai H, Azuma M, Okumura K, Saito I, Miyasaka N: The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Arthritis Rheum 39:110-114, 1996
25. El-Gabalawy H, Gallatin M, Vazeux R, Peterman G, Wilkins J: Expression of ICAM-R (ICAM-3), a novel counter-receptor for LFA-1, in rheumatoid and nonrheumatoid synovium: comparison with other adhesion molecules. Arthritis Rheum 37:846-854, 1994
26. Boots AM, Wimmers-Bertens AJ, Rijnders AW: Antigen-presenting capacity of rheumatoid synovial fibroblasts. Immunology 82:268-274, 1994
27. Alsalameh S, Jahn B, Krause A, Kalden JR, Burmester GR: Antigenicity and accessory cell function of human articular chondrocytes. J Rheumatol 18:414-421, 1991
28. Thomas R. Davis LS, Lipsky PE: Rheumatoid synovium is enriched in mature antigen-presentins dendritic cells. J Immunol 152:2613-2623, 1994
29. Ziff M: Relation of cellular infiltration of rheumatoid synovial membrane to its immune response. Arthritis Rheum 17:313-319, 1974
30. Burmester GR, Dimitriu-Bona A, Waters SJ, Winchester RJ: Identification of three major synovial lining cell populations by monoclonal antibodies directed to la antigens and antigens associated with monocyte/macrophages and fibroblasts. Scand J Immunol 17:69-81, 1983
31. Burmester GR, Jahn B, Rohwer R, Zacher J, Winchester RJ, Kalden JR: Differential expression of Ia antigen by rheumatoid synovial lininc cells. J Clin Invest 80:595-604, 1987
32. Firestein GS, Zvaifler NJ: Peripheral blood and synovial fluid monocyte activation in inflammatory arthritis: low levels of synovial fluid and synovial tissue interferon suggest that γ-interferon is not the primary macrophage activating factor. Arthritis Rheum 30:864-871, 1987
33. Soden M, Rooney M, Whelan A, Feighery C, Bresnihan B: Immunohistological analysis of the synovial membrane: search for predictors of the clinical course in rheumatoid arthritis. Ann Rheum Dis 50:673-676, 1991
34. Mulherin D, Fitzgerald O, Bresnihan B: Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 39:115-124, 1996
35. Iguchi T, Kurosaka M, Ziff M: Electron microscopic study of HLA-DR monocyte/macrophage staining cells in the rheumatoid synovial membrane. Arthritis Rheum 29:600-613, 1986
36. Sack U, Stiehl P, Geiler G: Distribution of macrophages in rheumatoid synovial membrane and its association with basic activity. Rheumatol Int 13:181-186, 1994
37. Fassbender GH: Histomorpholocial basis of articular cartilage destruction in rheumatoid arthritis. Coll Relat Res 3:141-155, 1983
38. Barthel R, Stuhlmüller B, Keyszer G, Burmester GR: Macrophage and monocyte activation in rheumatoid arthritis and its therapeutic implication. EULAR J 24:33-35, 1995
39. Stuhlmüller B, Burmester GR: Analysis of gene expression by activated monocytes from patients with rheumatoid arthritis (abstract). Arthritis Rheum 37 (suppl 9):S38U, 1994
40. Remick DG, DeForge LE, Sullivan JF, Showell HJ: Profile of cytokines in synovial fluid specimens from patients with arthritis: interleukin 8 (IL-8) and IL-6 correlate with inflammatory arthritides. Immunol Invest 2:321-327, 1992
41. Seitz M, Dewald B, Gerber N, Baggiolini M: Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis. J Clin Invest 87:463-469, 1991
42. Seitz M, Dewald B, Ceska M, Gerber N, Baggiolini M: Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thipmalate and methotrexate. Rheumatol Int 12:159-164, 1992
43. Peichl P, Ceska M, Effenberger F, Haberbauer G, Broell H, Lindley IJD: Presence of NAP-1/IL-8 in synovial fluids indicates a possible pathogenic role in rheumatoid arthritis. Scand J Immunol 34:333-339, 1991
44. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines G, Burdick MD, Pope RM, Stricter RM: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 90:772-779, 1992
45. Loetscher P, Dewald B, Baggiolini M, Seitz M: Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes: effects of anti-rheumatic drugs. Cytokine 6:162-170, 1994
46. Goethe R, van Phi L: The far upstream chicken lysozyme enhancer at -6.1 kilobase, by interacting with NF-M, mediates lipopolysaccharide-induced expression of the chicken lysozyme gene in chicken myelomonocytic cells. J Biochem 269:31302-31309, 1994
47. Handel ML, McMorrow LB, Gravallese EM: Nuclear factor-κB in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 38:1762-1770, 1995
48. Donelly RP, Crofford LJ, Freeman SL, Buras J, Remmers E, Wilder RL, Fenton MJ: Tissue-specific regulation of IL-6 production by IL-4. J Immunol 151:5603-5612, 1993
49. Katsikis PD, Chu C-Q, Brennan FM, Maini RN, Feldman M: Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 179:1517-1527, 1994
50. Llorente L, Richaud-Patin Y, Fior R, Alcocer-Varela J, Wijdenes J, Morel Fourrier B, Galanaud P, Emilie D: In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus: a potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 37:1647-1655, 1994
51. Hart PH, Ahern MJ, Smith MD, Finlay-Jones JJ: Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis. Immunology 84:536-542, 1995
52. Chomarat P, Banchereau J, Miossec P: Differential effects of interleukins 10 and 4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis. Arthritis Rheum 38:1046-1054, 1995
53. Wu PWP, Siegel MI, Egan RW, Billah MM: Interleukin (IL)-10 inhibits nuclear factor KB (NFκB) activation in human monocytes. J Biol Chem 270:9558-9563, 1995
54. Rocken M, Urban J, Shevach EM: Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo. J Exp Med 179:1885-1893, 1994
55. Bogdan C, Paik J, Vodovotz Y, Nathan C: Contrasting mechanisms for suppression of macrophage cytokine release of transforming growth factor-beta and interleukin-10. J Biol Chem 267:23301-23308, 1992
56. Sengupta TK, Chen A, Zhong Z, Darnell JE Jr, Ivashkiv LB: Activation of monocyte effector genes and STAT family transcription factors by inflammatory synovial fluid independent of interferon-γ. J Exp Med 181:1015-1025, 1995
57. Lacraz S, Isler P, Vey E, Welgus HG, Dayer J-M: Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem 269: 22027-22033, 1994
58. Janson RW, Hance KR, Arend WP: Production of IL-1 receptor antagonist by in vitro-derived macrophages: effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor. J Immunol 147:4218-4234, 1991
59. Jenkins JK, Arend WP: Interleukin 1 receptor antagonist in human monocytes is induced by IL-1, IL-3, IL-4 and GM-CSF. Cytokine 5:404-415, 1993
60. Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, Arend WP: Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 37:644-652, 1994
61. Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN: Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol 31:653-661, 1992
62. Tetlow LC, Lees M, Woolley DE: Comparative studies of collagenase and stromelysin-1 expression by rheumatoid synoviocytes in vitro. Virchows Arch 425:569-576, 1995
63. Tetlow LC, Lees M, Ogata Y, Nagase H, Woolley DE: Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo. Rheumatol Int 13:53-59, 1993
64. Jensen HS, Jensen LT, Saxne T, Diamant M, Bendtzen K: Human monocyte elastolytic activity, the propeptides of types I and III procollagen, proteoglycans, and interleukin-6 in synovial fluid from patients with arthritis. Clin Exp Rheumatol 9:391-394, 1991
65. Chang JS, Quinn JM, Demaziere A, Bulstrode CJ, Francis MJ, Duthie RB, Athanasou NA: Bone resorption by cells isolated from rheumatoid synovium. Ann Rheum Dis 5:1223-1229, 1992
66. Keyszer GM, Heer AH, Gay S: Cytokines and onkogenes in cellular interactions of rheumatoid arthritis. Stem Cells (Dayt) 12:75-86, 1994
67. Janusz MJ, Hare M: Cartilage degradation by cocultures of transformed macrophage and fibroblast cell lines: a model of metalloproteinase-mediated connective tissue degradation. J Immunol 150:1922-1931, 1993
68. Remmers EF, Sano H, Lafyatis R, Case JP, Kumkumian GK, HIa T, Maciag T, Wilder RL: Production of platelet derived growth factor B chain (PDGF-B/c-sis) mRNA and immunoreactive PDGF B-like polypeptide by rheumatoid synovium: coexpression with heparin binding acidic fibroblast growth factor-1. J Rheumatol 18:7-13, 1991
69. Lafyatis R, Remmers EF, Roberts AAB, Yocum DE, Wilder R: Anchorage independent growth of synoviocytes from arthritic and normal joints: stimulation from exogenous plateled derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest 83:1267-1276, 1989
70. MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI: Differential effects of IL-1 and TNA α on the expression of stromeolysin, collagenase and their natural inhibitor TIMP, in rheumatoid synovial fibroblasts. Matrix Biol 1:198-199, 1992
71. Krane SM, Conca W, Stephenson ML, Amento EP, Goldring MB: Mechanisms of matrix degradation in rheumatoid arthritis. Ann N Y Acad Sci 580:340-354, 1990
72. Bedard PA, Golds EE: Cytokine-induced expression of mRNAs for chemotactic factors in human synovial cells and fibroblasts. J Cell Physiol 154:433-441, 1993
73. Akahoshi T, Wada C, Endo H, Hirota K, Hosaka S, Takagishi K, Kondo H, Kashiwazaki S, Matsushima K: Expression of monocyte chemotactic and activating factor in rheumatoid arthritis: regulation of its production in synovial cells by interieukin-1 and tumor necrosis factor. Arthritis Rheum 36:762-771, 1993
74. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Einer VM, Einer SG, Stricter RM: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798-1801, 1992
75. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini P: Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376:517-519, 1995
76. Kriegsmann J, Keyszer G, Geiler T, Brauer R, Gay RE, Gay S: Expression of vascular cell adhesion molecule 1 (VCAM-1) in rheumatoid synovium, demonstrated by in situ hybridization and immunohistochemistry. Lab Invest 72:209-214, 1995
77. Kriegsmann J, Keyszer G, Geiler T, Lagoo AS, Lagoo-Deenadayalan S, Gay RE, Gay S: Expression of E-selectin messenger RNA and protein in rheumatoid arthritis. Arthritis Rheum 38:750-754, 1995
78. Greenwald RA, Diamond HS, editors: CRC Handbook of Animal Models for the Rheumatic Diseases. Boca Raton, FL, CRC Press, 1988
79. Pernille MG: Evidence for two distinct types of synoviocytes in rat synovial membrane. J Ultrastruct Res 78:321-339, 1982
80. Verschure PJ, van Noorden CJF, Dijkstra CD: Macrophages and dendritic cells during the early stages of antigen-induced arthritis in rats: immunohistochemical analysis of cryostat sections of the whole knee joint. Scand J Immunol 29:371-381, 1989
81. Skaleric U, Allen JB, Smith PD, Mergenhagen SE, Wahl SM: Inhibitors of reactive oxygen intermediates suppress bacterial cell wall-induced arthritis. J Immunol 147:2559-2564, 1991
82. Pelegri C, Franch A, Castellote C, Castell M: Immunohistochemical changes in synovial tissue during the course of adjuvant arthritis. J Rheumatol 22:124-134, 1995
83. Edwards JCW: The origin of type A synovial lining cells. Immunobiology 161:227-231, 1982
84. Issekutz AC, Issekutz TB: Monocyte migration to arthritis in the rat utilizes both CD11/CD18 and very late activation antigen 4 integrin mechanisms. J Exp Med 181:1197-1203, 1995
85. Dijkstra CD, Döpp EA, Vogels IMC, van Noorden CJF: Macrophages and dendritic cells in antigen-induced arthritis: an immunohistochemical study using cryostat sections of the whole knee joint of rat. Scand J Immunol 26:513-523, 1987
86. Van den Berg TK, Breve JJP, Damoiseaux JGMC, Döpp EA, Keims S, Crocker PR, Dijkstra CD, Kraal G: Sialoadhesin on macrophages: its identification as a lymphocyte adhesion molecule. J Exp Med 176:647-655, 1992
87. Damoiseaux JGMC, Huitinga I, Döpp EA, Dijkstra CD: Expression of the ED3 antigen on rat macrophages in relation to experimental autoimmune diseases. Immunobiology 84:311-320, 1992
88. Johnson WJ, Muirhead KA, Meunier PC, Votta BJ, Schmitt TC, DiMartino MJ, Hanna N: Macrophage activation in rat models of inflammation and arthritis: systemic activation precedes arthritis induction and progression. Arthritis Rheum 29:1122-1130, 1986
89. López-Bote JP, Bernabeu C, Marquet A, Fernandez JM, Larraga V: Adjuvant-induced polyarthritis: synovial cell activation prior to polyarthritis onset. Arthritis Rheum 31:769-775, 1988
90. Miesel R, Zuber M: Copper-dependent antioxidase defenses in inflammatory and autoimmune rheumatic disease. Inflammation 17:283-294, 1993
91. 2 superoxide dismutase in murine model of acute and chronic inflammation. Inflammation 17:595-611, 1993
92. McCartney-Francis N, Allen JB, Mizel DE, Albina JE, Xie W, Nathan CF, Wahl SM: Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 178:749-754, 1993
93. Ialenti A, Moncada S, Di Rosa M: Modulation of adjuvant arthritis by endogenous nitric oxide. Br J Pharmacol 110:701-706, 1993
94. Mertz PM, DeWitt L, Stetler-Stevenson WG, Wahl LM: Interleukin 10 suppression of monocyte prostaglandin H synthase-2: mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J Biol Chem 269:21322-21329, 1994
95. Singer II, Kawka DW, Bayne EK, Donatelli SA, Weidner JR, Williams HR, Ayala JM, Mumford RA, Lark MW, Giant TT, Nabozny H, David CS: VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis. J Clin Invest 95:2178-2186, 1995
96. Henderson B, Rowe FM, Bird CR, Gearing AJH: Production of interleukin 1 in the joint during the development of antigen-induced arthritis in the rabbit. Clin Exp Immunol 74:371-376, 1988
97. Smith-Oliver T, Noel LS, Stimpson S, Yarnall DP, Connolly KM: Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 5:298-304, 1993
98. Johnson WJ, DiMartino MJ, Hanna N: Macrophage activation in rat models of inflammation and arthritis: determination of markers of stages of activation. Cell Immunol 103:54-64, 1986
99. Seitz M, Zwicker M, Pichler W, Gerber N: Activation and differentiation of myelomonocytic cells in rheumatoid arthritis and healthy individuals - evidence for antagonistic in vitro regulation by interferon-γ and tumor necrosis factor α, granulocyte monocyte colony stimulating factor and interleukin 1. J Rheumatol 19:1038-1044, 1992
100. Fujii I, Shingu M, Nobunaga M: Monocyte activation in early onset rheumatoid arthritis. Ann Rheum Dis 49:497-503, 1990
101. Binderup L: Lymphocyte-macrophage co-operation during induction of T-suppressor activity in rats with adjuvant arthritis. Ann Rheum Dis 42:687-692, 1983
102. Gilman SC, Daniels JF, Wilson RE, Carlson P, Lewis AJ: Lymphoid abnormalities in rats with adjuvant arthritis. I. Mitogen responsiveness and lymphokine synthesis. Ann Rheum Dis 43: 847-855, 1984
103. Lee JC, Rebar L, Demuth S, Hanna N: Suppressed IL-2 production and response in AA rats: role of suppressor cells and the effect of auranofin treatment. J Rheumatol 12:885-891, 1985
104. Müssener A, Klareskog L, Lorentzen JC, Kleinau S: TNF-alpha dominates cytokine mRNA expression in lymphoid tissues of rats developing collagen- and oil-induced arthritis. Scand J Immunol 42:128-134, 1995
105. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025-4031, 1991
106. Saxne T, Palladino MA Jr, Heinegård D, Talal N, Wollheim FA: Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31:1041-1045, 1988
107. Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C: Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 49:665-667, 1990
108. Horn JT, Bendele AM, Carlson DG: In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice. J Immunol 141:834-841, 1988
109. Van de Loo FAJ, Joosten LAB, van Lent PLEM, Arntz OJ, van den Berg WB: Roie of interleukin-1, tumour necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 38:164-172, 1995
110. Feige U, Karbowski A, Rordorf-Adam C, Pataki A: Arthritis induced by countinuous infusion of hr-interleukin-1 alpha into the rabbit knee joint. Int J Tissue React 11:225-238, 1989
111. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W: Evolution of collagen arthritis is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or recombinant soluble TNF receptor. J Immunol 77:510-514, 1992
112. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino AM: Involvement of endogenous tumour necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 89:7375-7379, 1992
113. Williams RO, Feldmann M, Maini RN: Anti-tumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89:9784-9788, 1992
114. Issekutz AC, Maeger A, Otterness I, Issekutz TB: The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T-lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin Exp Immunol 97:26-32, 1994
115. Probert L, Plows D, Kontogeorgos G, Kollias G: The type I interleukin-1 receptor acts in series with tumour necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 25:1794-1797, 1995
116. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 39:797-809, 1996
117. Sher A, Gazzinelli RT, Oswald IP, Clerici M, Kullberg M, Pearce EJ, Berzofsky JA, Mosman TR, James SL, Morse HC: Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev 127: 183-204, 1992
118. Hart PH, Ahern MJ, Smith MD, Finlay-Jones JJ: Regulatory effects of IL-13 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis. Clin Exp Immunol 99:331-337, 1995
119. Allen JB, Wong HL, Costa GL, Bienkowski MJ, Wahl SM: Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol 151:4344-4351, 1993
120. Kasama T, Stricter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL: Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 95:2868-2876, 1995
121. Van Rooijen N: The liposome-mediated "suicide" technique. J Immunol Methods 124:1-6, 1989
122. Flora L; Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis Rheum 22:340-346, 1979
123. Schmidt-Weber CB, Rittig M, Buchner E, Hauser I, Schmidt I, Palombo-Kinne E, Emmrich F, Kinne RW: Apoptotic cell death in activated monocytes following incorporation of clodronate-liposomes. J Leukoc Biol 60:230-244, 1996
124. Wyllie AH, Kerr JFR, Currie AR: Cell death: the significance of apoptosis. Int Rev Cytol 68:251-306, 1980
125. Camilleri JP, Williams AS, Amos N, Douglas-Jones AG, Love WG: The effect of free and liposome-encapsulated clodronate on the hepatic mononuclear phagocyte system in the rat. Clin Exp Immunol 99:269-275, 1995
126. Kinne RW, Schmidt-Weber CB, Hoppe R, Buchner E, Palombo-Kinne E, Nürnberg E, Emmrich F: Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum 38:1777-1790, 1995
127. Kinne RW, Schmidt C, Buchner E, Hoppe R, Nürnberg E, Emmrich F: Treatment of rat arthritides with clodronate-containing liposomes. Scand J Rheumatol 23:83-89, 1995
128. Edmonds JP, Scott DL, Fürst DE, Brooks P, Paulus HE: Anti-rheumatic drugs: a proposed new classification. Arthritis Rheum 36:336-339, 1993
129. Walz DT, DiMartino MJ, Misher A: Suppression of adjuvant arthritis in the rat by gold sodium thiomalate. Arm Rheum Dis 30:303-306, 1971
130. Van Lent PLEM, van den Bersselaar LAM, Holthuyzen AEM, van Rooijen N, van de Putte LBA, van den Berg WB: Phagocytic synovial lining cells in chronic experimental arthritis: downregulation of synovitis by C12MDP-liposomes. Rheumatol Int 13:221-228, 1994
131. Van Lent PLEM, van den Hoek AEM, van den Bersselaar LAM, Spanjaards MFR, van Rooijen N, Dijkstra CD, van de Putte LBA, van den Berg WB: In vivo role of phagocytic synovial lining cells in onset of experimental arthritis. Am J Pathol 143:1226-1237, 1993
132. Norton WL, Lewis DC, Ziff M: Electron-dense deposits following injection of gold sodium thiomalate and thiomalic acid. Arthritis Rheum 11:436-443, 1968
133. Scheinberg MA, Santos M, Finkelstein AE: The effects of auranofin and sodium aurothiomalate on peripheral blood monocytes. J Rheumatol 9:366-369, 1982
134. Harth M, Keown PA, Orange JF: Monocyte dependent excited oxygen radical generation in rheumatoid arthritis: inhibition by gold sodium thiomalate. J Rheumatol 10:701-707, 1983
135. Danis VA, Kuiesz AJ, Nelson DS, Brooks PM: The effect of gold sodium thiomalate and auranofin on lipopolysaccaride-induced interleukin-1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis. Clin Exp Immunol 79:335-340, 1990
136. Lipsky PE, Ziff M: Inhibition of antigen- and mitogen-induced human lymphocyte proliferation by gold compounds. J Clin Invest 59:455-466, 1977
137. Koch AE, Burrows JC, Polverine PJ, Cho M, Leibovich SJ: Thiol-containing compounds inhibit the production of monocyte/ macrophage-derived angiogenic activity. Agents Actions 34:350-357, 1991
138. Nesher G, Moore TL, Dorner RW: In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmetionine. Ann Rheum Dis 50:637-641, 1991
139. Seitz M, Loetscher P, Dewatd B, Towbin H, Rordorf C, Gallati H, Baggiolini M, Gerber NJ: Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 34:602-609, 1995
140. Amano Y, Lee SW, Allison AC: Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: mediation by decreased mRNA stability. Mol Pharmacol 43:176-182, 1993
141. Karsh J, Wright DG, Klippel JH, Decker JL, Deisseroth AB, Flye MW: Lymphocyte depletion by continuous flow cell centrifugation in rheumatoid arthritis: clinical effects. Arthritis Rheum 22:1055-1059, 1979
142. Tenenbaum J, Urowitz MB, Keystone EC, Dwosh IL, Curtis JE: Leukapheresis in severe rheumatoid arthritis. Ann Rheum Dis 3:40-44, 1979
143. Yeadon C, Karsh J: Lymphapheresis in rheumatoid arthritis: the clinical and laboratory effects of limited course of cell depletion. Clin Exp Rheumatol 1:119-124, 1983
144. Burmester GR, Beck P, Eife R, Peter HH, Kalden JR: Induction of a lymphotoxin-like mediator in peripheral blood and synovial fluid lymphocytes by incubation with synovial fluid from patients with rheumatoid arthritis. Rheumatol Int 1:139-143, 1981
145. MacKinnon SK, Starkebaum G: Monocyte Fc receptor function in rheumatoid arthritis: enhanced cell-binding of IgG induced rheumatoid factors. Arthritis Rheum 30:498-506, 1987
146. Murray HW, Stern JI, Weite K, Rubin BY, Carriero SM, Nathan CF: Experimental visceral leishmaniasis production of interleukin-2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin-2 and interferon-gamma. J Immunol 138:2290-2297, 1987
147. Gold CI, Sonnenfeld G: Effect of treatment with interferon-gamma and concanavalin A on the course of infection of mice with Salmonella typhimurium strain. J Interferon Cytokine Res 7:635-639, 1987
148. Burmester GR, Yu DTY, Irani A-M, Kunkel HG, Winchester RJ: Ia+ T cells in synovial fluid and tissues of patients with rheumatoid arthritis. Arthritis Rheum 24:1370-1376, 1981
149. Burmester GR, Jahn B, Gramatzki M, Zacher J, Kalden JR: Activated T cells in vivo and in vitro: different phenotypic expression of Tac and Ia antigens in patients with inflammatory joint diseases and normal in vitro activated T cells. J Immunol 133:1230-1234, 1984
150. Potocnik AJ, Menninger H, Yang SH, Pirner K, Krause A, Burmester GR, Broker BM, Heppt P, Weseloh G, Michels H, Truckenbrodt H, Emmrich F, Groczek R: Expression of the CD2 activation epitope T11-3 (CD2R) on T cells in rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, and Lyme disease: phenotypic and functional analysis. Scand J Immunol 34:351-358, 1991
151. Firestein GS, Xu WD, Townsend T, Broide D, Alvaro-Gracia Y, Glasebrook A, Zvaifler NJ: Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin-2 and interleukin-3) and presence of macrophage colony-stimulating factor (CSF-I) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 168:1573-1586, 1988
152. Dayer J-M, Burger D: Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur Cytokine Netw 5:563-571, 1994
153. Arend WP, Dayer J-M: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 38:151-160, 1995
154. Elliot MJ, Maini RN, Feldman M, Long-Fox A, Charles P, Bijl H, Woody JN: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344:1125-1127, 1994
155. Elliot MJ, Maini RN, Feldman M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody TN: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110, 1994
156. Lemmel EM, Franke M, Gaus W, Hartl PW, Hofschneider PH, Miehlke K, Machalke M, Obert HJ: Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int 7:127-132, 1987
157. Stefanovic-Racic M, Meyers K, Metschter C, Coffey JW, Hoffmann RA, Evans CH: N-monomethyl arginine, an inhibitor of nitric oxide synthase suppresses the development of adjuvant arthritis in rats. Arthritis Rheum 37:1062-1069, 1994
158. Greenwald RA, Moack SA, Ramamurthy NS, Golub LM: Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis, and in combination with flubiprofen, ameliorate bone damage. J Rheumatol 19:927-938, 1992
159. Conway JG, Wakefield JA, Brown RH, Marron BE, Sekut L, Stimpson SA, McElroy A, Menius JA, Jeffreys JJ, Clark RL: Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med 182:449-457, 1995
160. Billingham MEJ, Hicks C, Carney S: Monoclonal antibodies and arthritis. Agents Actions 29:77-87, 1990
161. Van den Broek MF, van den Berg WB, van de Putte LBA: The role of MHC class II antigens in the flare up reaction of antigen-induced arthritis in mice. Agents Actions 5:328-330, 1986
162. Wooley PH, Luthra HS, Lafuse P, Huse A, Stuart JM, David CS: Type II collagen-induced arthritis in mice. III. Suppression of arthritis using monoclonal and polyclonal anti-Ia antisera. J Immunol 134:2366-2374, 1985
163. Cooper SM, Sriram R, Ranges GE: Suppression of murine collagen-induced arthritis with monoclonal anti-Ia antibodies and augmentation with IFN-γ. J Immunol 141:1958-1962, 1988
164. Iigo Y, Takasbi T, Tamatani T, Miyasaka M, Higashida T, Yagita H, Okumura K, Tsukada W: ICAM-1-dependent pathway is critically involved in the pathogenesis of adjuvant arthritis in rats. J Immunol 147:4167-4171, 1991
165. Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, Lipsky PE: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 37:992-999, 1994
166. Rankin KC, Choy KH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi GS: The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 34:334-342, 1995
167. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, and the IL-1Ra Arthritis Study Group: Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 39:1092-1101, 1996
168. Bertrand JJ, Waine H, Tobias LA: Distribution of gold in the animal body in relation to arthritis. J Lab Clin Med 33:1133-1138, 1948
169. Lawrence JS: Studies with radioactive gold. Ann Rheum Dis 20:341-352, 1961
170. Lee JC, Rebar L, Demuth S, Hanna N: Suppressed IL-2 production and response in AA rats: role of suppressor cells and the effect of auranofin treatment. J Rheumatol 12:885-891, 1985
171. Jessop JD, Vernon-Roberts B, Harris J: Effects of gold salt and prednisolone on inflammatory cells. I. Phagocytic activity of macrophages and polymorphs in inflammatory exudates studied by a skin windows technique in rheumatoid and control patients. Ann Rheum Dis 32:294-300, 1973
172. Champion GD, Graham GG, Ziegler JB: The gold complex. Baillieres Clin Rheumatol 4:491-534, 1990
173. Hu SK, Mitch YL, Oronsky AL, Kewar SS: Studies on the effect of methotrexate on macrophage function. J Rheumatol 15:206-209, 1988
174. Johnson WJ, DiMartino MJ, Meunier PC, Muirhead KA, Hanna N: Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant arthritis. J Rheumatol 15:745-749, 1988
175. Horn JT, Gliszczynski VL, Cole HW, Bendele AM: Interleukin-1 mediated acceleration of type II collagen-induced arthritis: effects of anti-inflammatory or anti-arthritic drugs. Agents Actions 33:300-309, 1988
176. Thomas R, Carroll GJ: Reduction of leukocyte and interleukin-1β concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 36:1244-1252, 1993
177. Williams AS, Camilleri JP, Topley N, Williams BD: Prostaglandin and tumor necrosis factor secretion by peritoneal macrophages isolated from normal and arthritic rats treated with liposomal methotrexate. J Pharmacol Toxicol Methods 32:53-58, 1994
178. Hirohata S, Yanagida T, Itoh K, Nakamura H, Yoshino S, Tomita T, Ochi T: Accelerated generation of CD14+ monocyte-lineage cells from the bone marrow of rheumatoid arthritis patients. Arthritis Rheum 39:836-843, 1996